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Estrogen for Male Function:  
Effect of Changes in the Sex 
Hormone Milieu on Erectile 
Function
Tomoya Kataoka and Kazunori Kimura
Abstract
Androgens are essential for male physical activity and normal erectile function. 
Moreover, estrogens also influence erectile function, and high estrogen levels are a risk 
factor for erectile dysfunction (ED). In this review, we summarize relevant research 
examining the effects of the sex hormone milieu on erectile function. Testosterone 
affects several organs, particularly erectile tissue. The mechanisms through which 
testosterone deficiency affects erectile function and the results of testosterone 
replacement therapy have been extensively studied. Estrogen, the female sexual 
hormone, also affects erectile function, as demonstrated in both clinical and basic 
studies. Interestingly, estradiol-testosterone imbalance is considered a risk factor for 
ED. Furthermore, endocrine-disrupting chemicals have estrogen-like effects and cause 
ED. Phosphodiesterase-5 (PDE-5) inhibitors, first-line drugs for the treatment of ED, 
increase the levels of testosterone and estradiol in patients with low testosterone levels. 
Therefore, estrogen levels should be carefully monitored in patients receiving PDE-5 
inhibitors. Future studies are needed to confirm these findings using molecular tools in 
order to provide insights into the treatment and mechanisms of endocrine-related ED.
Keywords: estrogen, testosterone, endocrine-disrupting chemical, 
phosphodiesterase-5 inhibitor, erectile dysfunction, endothelial function
1. Introduction
Serum estrogen levels are correlated with symptoms of aging in men, and estro-
gen may therefore play an important role in aging [1, 2]. Several previous studies 
have suggested that estrogen levels may also affect erectile function [3–6]. Indeed, 
older and obese men have been found to have not only low androgen levels but also 
high estrogen levels. Since testosterone is metabolized to estradiol by aromatase, the 
particularly high aromatase levels in visceral adipose tissue may explain the elevated 
estradiol levels among obese men [7]. Visceral adipose tissue often accumulates 
among men with increasing age. Interestingly, high estrogen levels have been 
observed in older patients who present with a lack of sexual interest and erectile 
dysfunction (ED); therefore, these symptoms in the elderly are thought to involve a 
pathophysiological estrogen-testosterone imbalance [6, 8–10].
Accordingly, in this review, we discuss the effects of sex hormone imbalances on 
male erectile function.
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2. Erectile function and sexual hormones
There are many reports on erectile function and sexual hormones. Erectile func-
tion is controlled by complex mechanisms [11], including the vascular and nervous 
systems [12–16]. One of the most important materials is a nitric oxide (NO). After 
NO is releasing in the penis, corporal smooth muscle relaxes. However, when NO 
production is decreased, the erectile function weakened, resulting in ED. The 
relaxant system is also important for the erectile function. The relaxant system is 
controlled by both the endothelial and the nervous systems. When the upper stream 
of smooth muscle relaxant system is weakened, ED is caused; therefore, many stud-
ies have focused on smooth muscle relaxation. In contrast, corporal smooth muscle 
contraction is controlled by constrictors, such as noradrenaline in the flaccid state. 
However, if the contraction be upregulated in some situations, ED would be caused.
Interestingly, some studies have indicated that smooth muscle relaxation and 
contraction balance is disturbed by abnormal activation of contractile signaling 
pathway such as the adrenergic regulation. In some syndromes causing ED, such as 
diabetes mellitus or metabolic syndrome, the contraction is enhanced [17–19]. One 
of the important contractile signaling pathways is the RhoA/Rho-kinase signaling 
pathway. The enhancement is known to occur in aged individuals. The inhibition of 
RhoA/Rho-kinase signaling pathway by Y-27632 has been shown to improve ED in 
aged animal models [20, 21]. Interestingly, the contractility of smooth muscle in the 
corpus cavernosum is regulated by sexual hormones and may play a significant role 
in erectile function.
3. Testosterone deficiency and ED
Testosterone deficiency and ED have been studied extensively [22–25]. 
Testosterone deficiency causes ED using castrated animal models [26]. 
Furthermore, the erectile function is discussed by the endothelial NO synthase 
(eNOS) and neuronal NOS (nNOS) signalings. In some studies, testosterone 
administration to the castrated animals improved NOS expression in the penis and 
restored the erectile function [27]. Li et al. showed that testosterone deficiency 
decreases the upregulating reactive oxygen species production and it decreased 
eNOS activity (the phospho-eNOS/eNOS ratio) [28]. They also showed the reduc-
tion in eNOS activity induced cGMP levels decreased in the penis. Testosterone 
also alters phosphodiesterase type 5 (PDE-5) expression in the penis. Traish et al. 
showed that testosterone deficiency decreases PDE-5 activity using the rabbit 
model [29]. Additionally, Zhang et al. showed that PDE-5 expression was decreased 
by castration in the rat corpus cavernosum and that testosterone replacement 
therapy to the rats improved the expression [30]. These results indicate that tes-
tosterone is important for regulating PDE-5 expression. Traish et al. also suggested 
testosterone regulates not only NOS but also PDE-5 [31].
Testosterone also affects the smooth muscle of the corpus cavernosum. Reilly 
et al. reported that testosterone deficiency reduces the number of α-adrenergic-1 
receptors in the castrated rats’ smooth fascia [32]. Moreover, testosterone modu-
lates the adrenergic response of the corpus cavernosum vascular smooth muscle 
[33]. These results indicate that when testosterone levels decrease, smooth muscle 
contractility also decreases. On the other hand, Sopko et al. showed that the lev-
els of RhoA and Rho-kinase proteins are increased in the castrated rats’ corpus 
cavernosum [34]. Their results indicated that testosterone deficiency increased 
smooth muscle contractility, leading to the decreasing erectile function and 
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hypertension. Thus, although testosterone deficiency may increase contraction, 
additional research is required to more fully elucidate its impact on smooth muscle 
contraction.
Interestingly, testosterone also directly affects smooth muscle relaxation. Using 
isometric tension analysis, Yue et al. showed that the smooth muscle of rabbit coro-
nary arteries and aortas are relaxed by testosterone [35]. Others have also reported 
that testosterone activates smooth muscle ATP-sensitive K+ channels and regulates 
the relax response of the smooth muscles [36]. These findings indicate that tes-
tosterone may regulate erectile function locally by acting on corpus cavernosum 
smooth muscle. These results indicate that testosterone may affect both genomic 
and nongenomic mechanisms of erectile function.
Testosterone also affects the structure of the penis. For example, castrated rats 
exhibit smooth muscle loss and fibrosis [37], and testosterone deficiency increases 
the volume of collagen in the internal pudendal arteries [38]. These effects of 
testosterone indicate that testosterone deficiency causes programmed trabecular 
smooth muscle cell death (apoptosis) [29]. Traish et al. also indicated that testos-
terone deficiency is related to the accumulation of fat-containing cells (fibroblasts 
or preadipocyte-like cells), particularly in the penis [39]. Interestingly, Wang et al. 
showed that testosterone deficiency decreases erectile function and increases colla-
gen in the corporeal cavernosum by inhibiting autophagy and promoting apoptosis 
of the smooth muscle cells in rats’ penis [40]. Although their report had several 
limitations, they discussed the important role of testosterone in regulating the 
structural integrity of the corpus cavernosum and erectile function. This resulted 
from testosterone regulating the counterregulation of autophagy and apoptosis 
by modulating the interactions between BECN1 and Bcl-2 (key dual regulators of 
autophagy and apoptosis) [41, 42].
4. Estrogen and ED in clinical studies
Estrogen, the female sex hormone, also affects erectile function. Interestingly, 
Tivesten et al. reported that that circulating free testosterone is positively associated 
with the ankle-brachial index (ABI) in a large population-based cohort of elderly 
males. They show that testosterone has a negative association with the degree of 
atherosclerotic disease in the lower extremities [43]. On the other hand, estrogen 
also has association with ABI negatively in the males, leading to higher estradiol 
levels associated with increased atherosclerosis. Besides, when lower extremity 
peripheral arterial disease (PAD) was defined as an ABI of less than 0.90, they 
showed that low serum testosterone and high serum estradiol are associated with 
lower extremity PAD. Moreover, both low testosterone levels and elevated estradiol 
levels affect erectile function and are associated with increased ED severity when 
present individually or concomitantly [44]. Low testosterone levels were thought 
to be the main effector; however, the presence of concomitantly elevated estradiol 
levels increased the severity of ED in patients with low testosterone levels. These 
reports indicated that female sex hormones also affect male health. Srilatha and 
Adaikan demonstrated that estradiol-testosterone imbalance is a risk factor for 
ED [8, 45, 46]. They showed that higher levels of estradiol were present in older 
patients experiencing with lack of sexual interest and ED, after adjustment for age 
[8]. Additionally, they concluded that the estradiol-testosterone hormonal balance 
may be a determinant of successful management outcomes for ED. Wu et al. also 
reported an association between sexual dysfunction and changes in estradiol and 
testosterone levels in Chinese men [47], and O’Connor et al. reported that estradiol 
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was associated with sexual function-related distress; higher levels were related to 
greater distress in 2838 men, ages 40–79 years, who completed the European Male 
Aging Study-Sexual Function Questionnaire [48]. These reports specifically dem-
onstrated the relationship between high estrogen milieu and male erectile function.
Serum estrogen levels are controlled by aromatase but can be altered under some 
conditions. Lamba et al. reported that antiretroviral therapy is associated with 
sexual dysfunction and increased serum estradiol levels in men [49]. Moreover, they 
found that total estradiol levels may be increased based on sex hormone-binding 
globulin (SHBG) levels. Drugs such as phenytoin are known to cause elevations 
in serum estradiol and SHBG [50]. Increased levels of SHBG, for example, due to 
induction of aromatase or SHBG synthetase, lead to a decrease in the free androgen 
index. Additionally, increased levels of SHBG and/or a low free androgen index 
have been associated with hypertension, osteoporosis, varicose veins, sexual dys-
function, and adverse serum lipids [51–56]. All these side effects have been reported 
in association with antiretroviral therapy as well. SHBG, similar to other globulins, 
is upregulated in patients with acquired immunodeficiency syndrome and human 
immunodeficiency virus infection [57, 58]. Hassan et al. have also reported the 
association of overhydration with male sexual dysfunction and depression in hemo-
dialysis patients [59]. They showed that overhydration in hemodialysis patients was 
associated with a higher prevalence of sexual dysfunction and depression, lower 
serum levels of total testosterone and dehydroepiandrosterone, and higher levels 
of serum estradiol. Intriguingly, Tivesten et al. reported that circulating estradiol is 
a predictor of the progression of carotid artery intima-media thickness in middle-
aged men [60]. They also reported that elderly men with low serum testosterone 
and estradiol have increased risk of mortality and that patients with low testos-
terone and estradiol levels have the highest risk of mortality [61]. Serum estrogen 
levels can be altered by some drugs and sex hormones. Therefore, ED induced by 
high estrogen may be related to mortality.
5. Estrogen and ED in basic research
Interestingly, estrogen administration decreases erectile function in animal 
models [62, 63]. Researchers administered estradiol orally to rats, resulting in high 
estradiol levels and low testosterone levels. Moreover, the intracavernous pressure 
(ICP) response to nerve stimulation was also impaired in all treated groups, and 
trichrome staining demonstrated the presence of cavernosal connective tissue 
hyperplasia in long-term study groups [62]. Oral administration of estradiol to rab-
bits resulted in high estradiol levels and low testosterone levels, similar to the effects 
in rats. Additionally, acetylcholine induced endothelium-mediated relaxation in 
normal animals, but this effect was significantly attenuated in treated groups, and 
NO-mediated nonadrenergic, noncholinergic neurotransmission was decreased in 
the treatment groups [63].
In our previous studies, subcutaneous administration (s.c.) of estradiol to rats 
resulted in high estradiol levels and low testosterone levels, thereby decreasing 
erectile function [64]. Moreover, we administered testosterone to rats with high 
estrogen-induced testosterone deficiency; however, erectile function did not 
improve. Interestingly, estrogen administration increases the contraction of smooth 
muscle in the corpus cavernosum, upregulating the RhoA/Rho-kinase signaling 
pathway, which is involved in ED [18]. Vignozzi et al. demonstrated that high-fat 
diet-induced ED is associated with high estradiol levels, rather than low testoster-
one levels [65].
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We also investigated the influence of estradiol-testosterone imbalance on 
erectile function in rats (Figures 1–6; Table 1). Male Wistar ST rats (11 weeks old, 
Japan SLC Inc., Hamamatsu, Japan) were separated into five groups. In the low 
testosterone (Low-T) group (n = 11), rats were injected with goserelin (LH-RH 
agonist, 0.9 mg/kg, s.c.). In the low testosterone and high estrogen (Low-T/High-E) 
group (n = 11), rats were injected with goserelin and estradiol (3 μg/kg/day, s.c.) 
daily from weeks 2 to 4. In the high estrogen (High-E) group (n = 11), rats were 
injected with estradiol daily from weeks 2 to 4. In the high estrogen and testosterone 
(High-E/High-T) group (n = 11), rats were injected with estradiol and testosterone 
(3 mg/kg/day, s.c.) daily from weeks 2 to 4. In the control group (n = 11), rats were 
not injected with any hormone. Table 1 shows the sex hormone concentrations in 
rats. Goserelin injection significantly decreased serum bioavailable testosterone 
(control: 1.20 ± 0.13 ng/mL, Low-T: 0.55 ± 0.04 ng/mL, P < 0.01 versus the control; 
Low-T/High-E: 0.73 ± 0.06 ng/mL, P < 0.05 versus the control). Testosterone injec-
tion significantly increased serum bioavailable testosterone (control: 1.20 ± 0.13 ng/
mL, High-E/High-T: 2.58 ± 0.31 ng/mL, P < 0.001 versus the control). Estradiol 
injection significantly increased serum estrogen (control: 102.5 ± 8.7 pg./
mL, Low-T/High-E: 275.4 ± 34.4 pg./mL, P < 0.01 versus the control; High-E: 
332.3 ± 17.4 pg./mL, P < 0.001 versus the control; High-E/High-T: 401.5 ± 51.6 pg./
mL, P < 0.001 versus the control).
Figure 2 shows the erectile response to electrical field stimulation of the cav-
ernous nerve in the different experimental groups. Analysis of the ICP/MAP ratio 
revealed that the ratios in the Low-T (0.52 ± 0.03), Low-T/High-E (0.46 ± 0.03), 
High-E (0.44 ± 0.03), and High-E/High-T (0.44 ± 0.02) groups, which represented 
Figure 1. 
Experimental design. In the control group, rats were injected with vehicle for 2 weeks. In the Low-T and High-E 
groups, rats were injected with goserelin acetate (LH-RH agonist, 0.9 mg/kg subcutaneously) at day 0. In the 
estrogen-treated (High-E) group, rats were injected with estradiol (3 mg/kg/day subcutaneously) for 2 weeks. In 
the estrogen- and testosterone-treated (High-E/High-T) group, rats were injected with estradiol (3 mg/kg/day 
subcutaneously) and testosterone (3 mg/kg/day subcutaneously) for 2 weeks. At the end of the period, rats were 
underwent erectile function testing in vivo or in vitro.
Estrogen
6
all treated rats, were significantly lower than in the control group (0.70 ± 0.04, 
P < 0.01). These data suggested that erectile responses were decreased in rats with a 
sex hormone imbalance.
Figure 3 shows the contractile response of rat corpora cavernosa strips to 
increasing concentrations of noradrenaline (NA). Increasing concentrations of 
NA were found to contract rat corpora cavernosa strips in all groups. In particular, 
10 μM NA resulted in statistically significant differences in the in vitro penile 
contractile response among the experimental groups (control: 154.5 ± 14.1%, Low-T: 
169.8 ± 14.8%, Low-T/High-E: 200.2 ± 21.1%, High-E: 198.9 ± 15.3%, High-E/High-T: 
249.7 ± 13.5%). Although the contractile response did not differ between the control 
Figure 2. 
Measurement of intracavernous pressure (ICP). Maximum ICP changes during electrical stimulation of the 
cavernous nerve in the control, Low-T, High-E, High-E/Low-T, and High-E/High-T groups. Data represent 
the means ± standard errors of the means (n = 6 per group). **P < 0.01 versus the control group by analysis of 
variance and Bonferroni-type multiple t-tests.
Figure 3. 
The contraction curves induced by noradrenaline (NA) in rat corpus cavernosum strips. The contractile tone 
induced by 80 mM KCl was taken as 100%. Data reported in all graphs represent the means ± standard errors 
of the means (n = 5 per group). *P < 0.05, **P < 0.01 versus the control group by analysis of variance and 
Bonferroni-type multiple t-tests. Emax values are reported in the text.
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group and the Low-T group (P > 0.05), the contractile responses in the Low-T/
High-E, High-E, and High-E/High-T groups were higher than the response in the 
control group (P < 0.05).
Figures 4 and 5 show the relaxant response of NA-precontracted rat corpora 
cavernosa strips to increasing concentrations of sodium nitroprusside (SNP) and 
Y-27632. In all groups, increasing concentrations of the NO donor SNP relaxed rat 
corpora cavernosa strips (control: Emax = 16.8 ± 10.3%, Low-T: Emax = 59.7 ± 7.6%, 
Low-T/High-E: Emax = 53.4 ± 5.0%, High-E: Emax = 55.2 ± 6.8%, High-E/High-T: 
Emax = 61.1 ± 1.5%). In the treated groups, the sensitivities to SNP were signifi-
cantly lower than in the control group (P < 0.01). Increasing concentrations of 
Figure 4. 
The relaxation curve induced by sodium nitroprusside (SNP) in rat corpus cavernosum strips. The strips were 
precontracted using 10−5 M NA. Data reported in all graphs represent the means ± standard errors of the means 
(n = 5 per group). *P < 0.05, **P < 0.01 versus the control group by analysis of variance and Bonferroni-type 
multiple t-tests. Emax values are reported in the text.
Figure 5. 
The relaxation curves induced by Rho-kinase inhibitor Y-27632 in rat corpus cavernosum strips. The strips were 
precontracted using 10−5 M NA. Data reported in all graphs represent the means ± standard errors of the means 
(n = 5 per group). *P < 0.05, **P < 0.01 versus the control group by analysis of variance and Bonferroni-type 
multiple t-tests. IC50 values are reported in the text.
Estrogen
8
Rho kinase inhibitor Y-27632 completely relaxed rat corpora cavernosa strips in 
all groups (control: half-maximal inhibitory concentration [IC50] = 1.22 × 10
−6 M, 
Low-T: IC50 = 2.43 × 10
−7 M, Low-T/High-E: IC50 = 1.31 × 10
−7 M, High-E: 
IC50 = 2.26 × 10
−7 M, High-E/High-T: IC50 = 1.25 × 10
−7 M). When using 10−6 M and 
10−5 M Y-27632, the sensitivities to Y-27632 in the treated groups were significantly 
lower than in the control group (P < 0.01); thus, the graphs for the treated groups 
were shifted to the left.
Figure 6 shows the histological analysis of the rats’ corpora cavernosa. The 
area ratio of the cavernous smooth muscle was analyzed (control: 10.5 ± 1.4%, 
Low-T: 7.4 ± 1.1%, Low-T/High-E: 13.2 ± 0.4%, High-E: 11.6 ± 0.1%, High-E/High-T: 
19.4 ± 1.1%). Similarly, the area ratio of the collagen fiber was analyzed (control: 
58.4 ± 2.5%, Low-T: 63.2 ± 3.0%, Low-T/High-E: 66.5 ± 2.3%, High-E: 58.8 ± 2.2%, 
High-E/High-T: 58.7 ± 1.4%). No statistically significant differences between the 
experimental groups were observed in the overall area ratios of smooth muscle, col-
lagen fiber, and other parameters according to χ2 tests for independence (P > 0.05). 
Figure 6. 
The rat penis sections of Masson’s trichrome staining. (A) Representative specimens of corpus cavernosum of 
each group rats. (B) Histological evaluation of the tissues. The area ratios of the collagen fibers, smooth muscle 
(SM), and others were calculated using computerized image analysis. Data reported in all graphs represent the 
means ± standard errors of the means (n = 3 per group).
Bio-T (ng/mL) Estrogen (pg/mL)
Control 1.20 ± 0.13 102.5 ± 8.7
Low-T 0.55 ± 0.04** 51.2 ± 4.2
High-E 0.90 ± 0.12 332.3 ± 17.4**
High-E/Low-T 0.73 ± 0.06* 275.4 ± 34.4**
High-E/High-T 2.58 ± 0.31** 401.5 ± 51.6**
Data are expressed as means ± standard errors of the means. *P < 0.05, **P < 0.01 versus the control group by analysis 
of variance and Bonferroni-type multiple t-tests (n = 6 per group).
Table 1. 
Serum levels of estrogen and bioavailable testosterone (bio-T) in rats.
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Overall, we demonstrated that changes in the sex hormone milieu affected erectile 
function in rats, and our hypothesis that the sex hormone imbalance associated 
with ED was supported by both in vivo and in vitro experiments using pharmaco-
logical tools.
6. Estrogen receptors (ERs) in erectile function
Several reports have suggested an association between ERs and ED. Schultheiss 
et al. have shown the ER distribution in the corpus cavernosum penis of adult 
humans [66]. Additionally, Dietrich et al. have demonstrated that the corpus 
cavernosum and corpus spongiosum smooth muscles were immunoreactive for the 
androgen receptor (AR), ER-α, and ER-β and that endothelial cells were negative 
for AR, sporadically positive for ER-α, and positive for ER-β [67]. Jesmin et al. have 
demonstrated that ER-α was predominantly localized in the sensory corpuscle of 
the glans penis [68]. On the bother hands, they also reported that the ER-β was 
localized around the neurovascular bundle, artery, and nerve [68]. Spyridopoulos 
et al. have shown that the potential antiapoptotic effects of estrogen were impaired 
by reduced ER-β expression, and loss of antiapoptotic genes in the rat corpus caver-
nosum was associated with the pathogenesis of ED [69]. These reports indicate that 
the ER exists in the corpus cavernosum and has various functions. Moreover, the 
ER has been reported to be altered under some conditions. Shirai et al. have demon-
strated that vascular endothelial growth factor treatment restores erectile function 
through stimulation of the insulin-like growth factor system and ER-β gene at 
the mRNA and protein levels in the corpus cavernosum of diabetic rats [70–72]. 
They had shown the expression of ER-β mRNA in male rat aortas before and after 
balloon denudation injury. Interestingly, the expression of ER-α mRNA in vascular 
endothelial and smooth muscle cells was very low levels after injury; however, the 
expression of ER-β mRNA in vascular endothelial cells was high after injury. Thus, 
the vascular protective effects of estrogen on endothelial and smooth muscle cells 
were exclusively mediated by ER-β, not ER-α [73]. Shirai et al. also demonstrated 
that the functionally predominant form of ER in the rat corpus cavernosum was 
ER-β and that age-related alterations in ER-β expression were likely related to the 
pathogenesis of ED in older rats. Thus, they concluded that downregulation of sex 
hormone receptors in the corpus cavernosum of aging rats is associated with ED 
[74]. Goyal et al. demonstrated the influence of estrogen on the structure of the 
corpus cavernosum [75–79] and showed that exposure to antiandrogens induces 
permanent structural abnormalities, including accumulation of fat cells, loss of 
smooth muscle cells and sinusoids, and reduced thickness of connective tissue 
trabeculae and tunica albuginea in the corpora cavernosa [76]. They also demon-
strated that the ER and AR mediate cavernous smooth muscle cell differentiation, 
as shown by downregulation of MYH11 expression at the mRNA and protein levels 
and by reduced immunohistochemical staining of smooth muscle alpha actin using 
rats [79]. Therefore, a high estrogen milieu and alterations in ER expression may 
affect erectile function.
7. Endocrine-disrupting chemicals and ED
Some endocrine-disrupting chemicals have physiological effects similar to those 
of estrogen. Bisphenol A (BPA) is a widely used endocrine-disrupting chemical that 
is thought to have adverse health effects [80]. BPA has been widely produced and 
used as a common ingredient in the manufacture of plastics. Humans are mainly 
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exposed to BPA through ingestion of foods containing BPA, and increasing evidence 
supports its association with impaired male reproductive function [81]. Manfo 
et al. reported that BPA also decreases erectile function [82], and Li et al. showed 
that BPA-exposed workers had significantly increased risk of ED (odds ratio = 4.5, 
95% confidence interval: 2.1–9.8) [83, 84]. Moon et al. were the first to report the 
influence of BPA on erectile function using animal model [85]. They observed 
thickening of tunica albuginea, subtunical deposition of fat, and decreased sinu-
soidal space with subsequent increases in trabecular smooth muscle content by 
histological analysis in BPA-treated animals and demonstrated endothelial dysfunc-
tion in BPA-treated rabbits. Kovanecz et al. also reported that BPA decreases nNOS 
and vascular endothelial growth factor expression in rats [86, 87]. In these reports, 
BPA-induced ED was similar to high estrogen-induced ED. Thus, the relationship 
between endocrine-disrupting chemicals and ED should be carefully considered.
8. ED treatment and estrogen
PDE-5 inhibitors are the first choice for patients with ED. Recently, some inter-
esting papers on PDE-5 inhibitors and estrogen have been published. Greco et al. 
reported a reduction in estrogen levels in patients with ED after chronic exposure to 
tadalafil, a PDE-5 inhibitor, and a concomitant increase in the testosterone-estrogen 
ratio [88]. They also showed that increased testosterone-estrogen ratios were not 
related to increases in testosterone serum levels, but rather to the possible effects of 
tadalafil on aromatase activity. Aversa et al. also demonstrated that daily tadalafil 
decreases serum estradiol levels [9]. In contrast, Spitzer et al. have reported that the 
PDE-5 inhibitor sildenafil increased estradiol levels in 40 men (ages 40–70 years) 
with ED, despite increasing testosterone levels [89]. Additionally, several reports 
have demonstrated that PDE-5 inhibitors increase testosterone levels [90–96]. 
When testosterone is low, estradiol levels may also be low because testosterone 
is metabolized to estradiol by aromatase. PDE-5 inhibitors can increase not only 
testosterone but also estradiol in patients with low testosterone levels. Therefore, 
estrogen levels should be carefully monitored in patients receiving PDE-5 
inhibitors.
9. Conclusions
The sex hormone milieu affects erectile function, and sex hormone imbalances, 
particularly low testosterone levels combined with high estrogen levels, cause 
ED. Interestingly, estradiol has protective effects on female health, but harmful 
effects on male erectile function. Overall, these results provide insights into the 
possible treatments of endocrine-related ED. Future research should confirm these 
findings in more specific experiments using molecular tools.
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